The success of drug-induced immunogenecity is contingent on the cell-surface expression or extracellular release of immunological adjuvants (i.e., DAMPs) by dying cancer cells to facilitate the maturation of DCs, leading to the priming and recruitment of CD8+ T cells8,35. Here, CD8A is linked to cancer.